Pneumocystis Infections

Slide 1 · Pneumocystis Infections

Host defense • Pulmonary pathology • Diagnostic interpretation

Opportunistic pulmonary mycosis

Dr Abu Suraih Sakhri

MBBS, MD (Pathology)

www.abusuraihsakhri.com

Slide 2 · Learning outcomes

Classify P. Jirovecii and explain why immune status governs clinical disease.

Recognize the defining alveolar and interstitial morphologic abnormalities.

Relate organism forms to silver staining, immunofluorescence, PCR and β-D-glucan.

Construct a differential diagnosis for diffuse infiltrates in an immunocompromised host.

Slide 3 · The organizing problem: Opportunistic pneumonia

Pneumocystis jirovecii is a yeast-like fungus with predominant pulmonary pathogenicity.

Disease is clinically important when the host’s immune defenses are compromised.

Its hallmark is a potentially rapidly progressive, bilateral pneumonia.

Organism

Compromised host

Pulmonary disease

Slide 4 · Position within human fungal infections

Four mycosis patterns

Superficial and cutaneous: Keratinized tissues

Subcutaneous: Skin, soft tissues, lymphatics

Endemic: Systemic infection may affect healthy hosts

Opportunistic: Severe disease with immunosuppression

Pneumocystis belongs here

Yeast-like fungal pathogen

A characteristic opportunistic pulmonary infection

Clinical expression depends strongly on host defense

Slide 5 · Why fungal identity matters

P. Jirovecii is a fungus, not a protozoan, despite its historical classification.

The source describes trophic, sporocytic, and cystic forms using older developmental terminology.

Cell-wall staining and direct organism detection are central to the morphologic diagnosis.

Fungal identity

Life forms

Targeted detection

Slide 6 · Pneumocystis versus ordinary fungal morphology

General fungal morphology

Yeasts grow as single oval or round cells, often budding.

Molds form filamentous hyphae.

Dimorphism describes shifts between yeast and mold forms.

P. Jirovecii

Described by trophic, sporocytic and cystic forms.

Cysts may show a cup-like or oval profile.

Classic diagnosis emphasizes organisms in alveolar material.

Slide 7 · Pulmonary tropism defines the presentation

The lung is the principal site of clinically recognized disease.

Involved air spaces contain abnormal eosinophilic, honeycombed material.

Alveolar septa may also become thickened by an interstitial inflammatory process.

Alveolar lumen

Alveolar septum

Clinical pneumonia

Slide 8 · The disease is a host–organism interaction

Exposure or acquisition

Host response

Clinical expression

Exposure alone is not equivalent to symptomatic Pneumocystis pneumonia.

The immune system usually clears early-life infection effectively.

Marked immune impairment shifts the balance toward clinically significant pneumonia.

Slide 9 · The AIDS epidemic established its importance

Pneumocystis pneumonia was a prominent opportunistic infection in AIDS during the 1980s.

It sometimes provided the initial clinical signal of advanced HIV disease.

The association illustrates the importance of cell-mediated immunity in pulmonary defense.

HIV-associated immune loss

Opportunistic fungus

Pneumonia

Slide 10 · Antiretroviral therapy changed the pattern

Untreated HIV

Effective ART

Lower PCP incidence

Robbins documents a marked decline in Pneumocystis pneumonia after effective ART became available.

The lower incidence reflects improved host immune competence; It does not mean eradication.

The risk remains relevant in patients with significant immune impairment.

Slide 11 · Pneumocystis remains clinically consequential

Residual US hospitalizations from Pneumocystis infection in 2017.

Although incidence has declined, Pneumocystis infections still result in hospitalization.

Historical declines should not obscure the risk in contemporary immunocompromised patients.

Lower incidence

Persistent cases

Clinical vigilance

Slide 12 · Outcome depends partly on care setting

Robbins gives an average mortality of symptomatic infection of approximately 10%–14%.

It states that mortality is higher in low-resource countries and some urban communities.

This is a textbook-level summary, not a risk prediction for an individual patient.

Severity

Health-system context

Outcome

Slide 13 · Asymptomatic acquisition versus symptomatic disease

Transient early acquisition

Most people are infected early in life.

In most hosts, infection is subsequently cleared effectively.

This history should not be equated with pneumonia.

Clinical Pneumocystis pneumonia

Occurs particularly in immunocompromised people.

May involve both lungs and progress rapidly.

Creates a distinct morphologic abnormality in alveoli.

Slide 14 · A clinically useful term: Opportunistic mycosis

An opportunistic infection exploits reduced effectiveness of host defenses.

Pneumocystis is a low-virulence pulmonary pathogen in the comparative framework of Robbins.

The same patient may also harbor other infection(s) or noninfectious pulmonary pathology.

Defective defense

Expanded differential

Multiple processes possible

Slide 15 · Three questions guide clinicopathologic reasoning

Is immunity impaired?

Does morphology fit?

Can the agent be demonstrated?

Risk context raises suspicion but is not proof of a specific organism.

Morphology provides anatomic evidence of the pneumonia pattern.

Organism-focused tests determine whether Pneumocystis is detected.

Slide 16 · Both arms of adaptive immunity respond

Robbins explicitly describes induction of humoral and cellular immune responses.

Cellular immunity is especially relevant to susceptibility in advanced HIV infection.

Interpret the host’s immune profile alongside microbiologic findings.

Humoral response

Cell-mediated response

Organism control

Slide 17 · Cell-mediated defense requires coordination

CD4⁺ helper T cells

Macrophage activation

Microbial control

CD4⁺ T-cell functions include CD40L signaling and cytokine-mediated macrophage activation.

Robbins relates loss of these pathways to impaired protection against opportunistic organisms.

The diagram represents general host-defense logic, not a fully defined Pneumocystis-specific pathway.

Slide 18 · Why CD4⁺ cells are clinically informative

HIV infection leads to numerical and functional defects in CD4⁺ T cells.

CD4⁺ cells coordinate important components of cellular and humoral immunity.

Loss of these cells helps explain susceptibility to infections such as Pneumocystis.

Fewer CD4⁺ cells

Weaker immune orchestration

Higher infection susceptibility

Slide 19 · The HIV-associated risk threshold

Robbins, in its lung chapter, states that Pneumocystis pneumonia usually occurs at CD4⁺ counts below 200 cells/mm³.

The threshold is a population-level clinical pattern, not a stand-alone diagnostic criterion.

A plausible presentation still requires evaluation of the pulmonary process.

CD4⁺ count

Risk enrichment

Diagnostic evaluation

Slide 20 · HIV-associated immune deterioration

HIV-mediated CD4⁺ injury

Impaired T-cell help

Opportunistic infection risk

HIV can reduce helper T-cell numbers through direct and indirect mechanisms.

Diminished T-cell functions impair antimicrobial responses in tissues.

Pneumocystis appears among the characteristic infections of advanced HIV disease.

Slide 21 · Qualitative dysfunction is also relevant

Reduced antigen-dependent T-cell proliferation in HIV infection.

Impairment of Th1-type responses contributes to defective cell-mediated immunity.

Host susceptibility should not be reduced to a single laboratory measurement.

Cell number

Cell function

Clinical risk

Slide 22 · Hyper-IgM syndrome provides a mechanistic example

CD40L or CD40 defects to susceptibility to P. Jirovecii pneumonia.

The important mechanism is compromised macrophage activation through CD40L–CD40 interactions.

The association illustrates a defect spanning T-cell help and downstream effector function.

CD40L/CD40 defect

Reduced macrophage activation

Pneumocystis susceptibility

Slide 23 · An immunodeficiency can affect several layers

T-cell help

Phagocyte activation

Organism clearance

Immunity is a network; Humoral and cellular responses are not isolated silos.

A defect in an upstream helper-cell signal may compromise downstream fungal control.

This framework explains susceptibility without assuming a unique organism-specific virulence factor.

Slide 24 · Defensive capacity: Stronger versus weaker

More effective host response

Most early-life infections are cleared.

Cellular and humoral immune responses are induced.

Symptomatic pneumonia is uncommon in the general population.

Reduced host response

Significant immunosuppression increases opportunity for disease.

Advanced HIV illustrates loss of cell-mediated defense.

A bilateral pulmonary process may develop.

Slide 25 · Immunosuppression is broader than HIV

Immune suppression due to disease, transplants, chemotherapy, or irradiation.

The lung chapter lists Pneumocystis among fungal causes of pneumonia in compromised hosts.

The specific nature of immune impairment guides the differential diagnosis.

Host condition

Predisposing therapy

Opportunistic differential

Slide 26 · Transmission: Airborne route is favored

Airborne transmission is believed to occur.

The wording reflects evidence for a route rather than complete certainty about each transmission event.

Its principal clinical consequence is pulmonary infection.

Probable airborne transfer

Respiratory exposure

Lung involvement

Slide 27 · The reservoir remains incompletely defined

No environmental source or external reservoir outside humans has been identified for P. Jirovecii.

Healthy individuals may contribute to the reservoir, according to evidence summarized by Robbins.

Distinguish an unidentified nonhuman reservoir from an established absence of transmission.

Nonhuman reservoir not identified

Potential human carriage

Unresolved ecology

Slide 28 · Early-life acquisition is usually transient

Acquisition in early life

Effective immune response

Clearance

Exposure/infection early in life for most individuals.

Subsequent effective clearance is the usual course.

Clinical pneumonia is associated with a different host-defense state.

Slide 29 · The organism is difficult to study in culture

Lack of a continuous in vitro culture method as a major experimental barrier.

This limits direct investigation of the organism’s biology and pathogenesis.

Direct detection in clinical material therefore has particular diagnostic importance.

Culture limitation

Pathogenesis knowledge gap

Specimen-based diagnosis

Slide 30 · What is known versus unresolved

Supported by the source

A fungal organism with several developmental forms

Predominantly pulmonary clinical disease

Probable airborne transmission

Humoral and cellular host responses

Major uncertainties in the source

No identified outside-human reservoir

No continuous laboratory culture method

Incomplete understanding of pathogenesis

Slide 31 · Developmental terminology: Three principal forms

Trophic forms

Sporocytic forms

Cystic forms

Robbins retains terms that originated when the organism was considered protozoal.

The forms differ in outline and detectability with wall-directed stains.

Do not assume that a negative wall stain excludes all organism forms.

Slide 32 · Trophic forms are not visualized by silver wall stain

Trophic forms are the smaller developmental forms in the Robbins description.

Methenamine silver highlights cell-wall-bearing forms rather than trophic forms.

Thus, a wall-directed stain displays only part of the organism population.

Original schematic — not a histologic image

Trophic profiles • wall stain does not display these forms

Slide 33 · Cystic forms provide a distinctive silhouette

Cysts that are cup-shaped or oval, sometimes with a central dot.

The silver-positive profiles are often described as “crushed ping-pong balls.”

These descriptions refer to diagnostic morphology, not a literal three-dimensional object.

Original schematic — not a histologic image

Cyst outlines • schematic cup or oval profiles

Slide 34 · Sporocytic and ascus forms: A wall-stain target

The source states that sporocyst and ascus forms are visualized with wall-directed stains.

Methenamine silver is the named example.

The terminology comes from the source and should not be read as a full lifecycle model.

Original schematic — not a histologic image

Silver-positive cystic profiles (schematic)

Slide 35 · Clusters may be found in lavage samples

Clusters of organisms in bronchoalveolar lavage fluid.

A cluster is a sample finding; It does not itself represent an alveolar histologic section.

Interpret the detected forms with the collection method and stain used.

Original schematic — not a histologic image

Organism clusters in sampled material • schematic

Slide 36 · The alveolar lumen contains foamy material

The characteristic luminal abnormality is eosinophilic, honeycombed (“foamy”) exudate.

This material occupies air spaces that normally support gas exchange.

Robbins Figure 8.45 also identifies accompanying interstitial inflammation.

Original schematic — not a histologic image

Foamy material in alveoli (schematic)

Slide 37 · The interstitium is also affected

Thickening of the alveolar interstitium.

Its Figure 8.45 caption identifies interstitial inflammation alongside foamy exudate.

Both septal and air-space compartments can therefore contribute to the lesion.

Original schematic — not a histologic image

Alveolar septa (schematic)

Slide 38 · Two simultaneous tissue compartments

Alveolar air space

Eosinophilic, honeycombed exudate

Organisms can be highlighted in alveolar material

The luminal component is prominent on routine stain

Alveolar septal/interstitial tissue

Increased septal thickness

Inflammatory response noted figure caption

The interstitial component modifies alveolar architecture

Slide 39 · A conceptual anatomy-to-function sequence

Luminal foamy exudate

Interstitial thickening

Impaired pulmonary function

The first two steps are the morphologic findings explicitly stated by Robbins.

The final arrow is an anatomic/pathophysiologic inference: Alveolar filling and thicker septa can interfere with gas exchange.

No numerical physiologic measurements are asserted.

Slide 40 · What the H&E pattern tells the pathologist

Examine air spaces for conspicuous finely vacuolated eosinophilic material.

Evaluate adjacent septa for interstitial thickening and inflammation.

H&E pattern recognition supports suspicion; Organism-directed techniques strengthen attribution.

Original schematic — not a histologic image

Foamy material in alveoli (schematic)

Slide 41 · What the silver stain contributes

Gömöri methenamine silver highlights cell-wall-bearing Pneumocystis forms.

Characteristic dark cyst profiles may be observed against alveolar contents.

The stain is not a general detector of trophic forms.

Original schematic — not a histologic image

Silver-positive cystic profiles (schematic)

Slide 42 · Routine morphology versus targeted fungal staining

Routine tissue stain (H&E)

Displays overall alveolar architecture

Shows foamy eosinophilic intra-alveolar exudate

Can demonstrate interstitial thickening

Methenamine silver

Highlights cell-wall-bearing forms

Can reveal characteristic cyst profiles

Does not demonstrate trophic forms reliably

Slide 43 · Morphology is specific only in combination

The foamy alveolar pattern is a strong morphologic clue within the relevant host context.

Cyst profiles on a suitable wall stain add organism-level evidence.

Diagnostic assays may be valuable when morphology or sampling is inconclusive.

Host

Morphology

Organism detection

Slide 44 · Bilateral pneumonia is a clinical pattern

P. Jirovecii can cause bilateral pneumonia.

A bilateral process is compatible with widespread alveolar involvement.

Distribution alone does not establish etiology in a compromised host.

Bilateral involvement

Competing causes

Microbial confirmation

Slide 45 · Rapid progression makes timely recognition important

The source specifically describes potentially rapidly progressive pneumonia.

Host vulnerability and a diffuse pulmonary process together merit urgent diagnostic attention.

Pathology contributes by connecting abnormal alveolar material to the organism.

Vulnerable host

Progressive disease

Timely assessment

Slide 46 · Extrapulmonary disease is uncommon

Robbins characterizes extra-pulmonary P. Jirovecii involvement as unusual.

When it occurs, infection is not limited to the alveolar compartment.

Do not interpret the possible sites as a routine dissemination pattern.

Predominantly pulmonary

Rare extension

Different tissue sites

Slide 47 · Reported extrapulmonary locations

Location

Teaching significance

Lymph nodes

Potential extra-pulmonary tissue involvement

Spleen

Possible systemic organ involvement

Bone marrow

A possible hematopoietic tissue site

Liver

A possible parenchymal organ site

Other sites

The source leaves open rarer locations

Slide 48 · A diagnostic specimen links airway and alveoli

Bronchoalveolar lavage (BAL) samples material from the lower respiratory tract.

Robbins specifically describes organism clusters in BAL fluid.

Specimen origin and disease context matter when interpreting detection.

Lower airway sampling

Organism-bearing material

Laboratory detection

Slide 49 · Diagnostic methods examine different targets

Morphology / stain

Immunofluorescence

Molecular testing

Morphology searches for characteristic organism forms and tissue reaction.

Fluorescein-conjugated antibody methods identify organism-associated antigen.

PCR detects organism-associated nucleic acid; These methods are not interchangeable.

Slide 50 · Direct immunofluorescence: Specific organism targeting

Fluorescein-conjugated antibody stains are commonly used.

Fluorescent labeling is directed to the organism rather than merely to the tissue-reaction pattern.

A stain result must still be read with specimen adequacy and clinical context.

Antibody probe

Organism recognition

Fluorescent signal

Slide 51 · PCR supplies a molecular detection route

Available PCR tests as sensitive and specific.

PCR targets microbial nucleic acid, unlike cell-wall stains or antibody-based microscopy.

A molecular result must be interpreted alongside host status and the overall clinical picture.

Clinical specimen

Nucleic acid target

PCR result

Slide 52 · Serum β-D-glucan is not organism-specific

That β-D-glucan increases with Pneumocystis infection.

It expressly cautions that the marker is not specific to Pneumocystis.

An elevated result cannot establish the species on its own.

Elevated marker

Fungal association

Species remains unproven

Slide 53 · Five diagnostic approaches are complementary

Method

Principal target

Central limitation

H&E

Alveolar tissue reaction

Pattern alone cannot establish species

Methenamine silver

Cell-wall-bearing cystic forms

Does not label trophic forms

Fluorescent antibody

Organism-associated antigen

Specimen interpretation still required

PCR

Pneumocystis nucleic acid

Must be integrated with clinical context

β-D-glucan

Circulating fungal wall-related marker

Not species-specific

Slide 54 · Wall stain versus antigen detection

Methenamine silver

Principle: Visualizes relevant wall material

Characteristic cyst outlines

Trophic forms are not shown

Fluorescein-conjugated antibody

Principle: Fluorescent antibody targeting

Organism-directed detection

A separate microscopy method with a distinct target

Slide 55 · Integrated clinicopathologic diagnosis

At-risk host

Compatible lung disease

Supportive organism evidence

The immune setting determines the prior plausibility of an opportunistic infection.

Pulmonary morphology supplies an anatomic correlate.

Direct staining, immunofluorescence or PCR supplies detection beyond a generic infiltrate.

Slide 56 · A negative single stain is not the entire workup

A wall stain detects only forms whose walls are highlighted by that technique.

Trophic forms therefore cannot be excluded from a specimen by their absence on silver stain.

Independent antibody-based and molecular diagnostic methods.

Target restriction

Sampling considerations

Complementary tests

Slide 57 · In a compromised host, more than one cause is possible

Robbins warns that pneumonia in immunocompromised patients may involve multiple pathogens.

Organisms other than Pneumocystis can cause diffuse pulmonary abnormalities.

Positive suspicion for one pathogen should not terminate evaluation of competing causes.

Opportunistic pathogen

Another infection

Noninfectious process

Slide 58 · Diffuse versus focal lung infiltrates

Diffuse infiltrates

Pneumocystis is listed among common causes.

CMV infection is another source-listed cause.

Drug reaction is an important noninfectious mimic.

Focal infiltrates

Gram-negative bacteria and S. Aureus are included.

Aspergillus is among the causes.

Malignancy may cause focal abnormalities.

Slide 59 · Differential in the immunocompromised lung

Candidate

Relevant clue from Robbins

Pneumocystis

Diffuse lung disease; foamy alveolar exudate; targeted detection

Cytomegalovirus

Included among common diffuse infiltrate causes

Drug reaction

Noninfectious diffuse-infiltrate cause

Aspergillus

Can cause invasive and necrotizing pulmonary lesions

Malignancy

Potential pulmonary infiltrate, including in HIV infection

Slide 60 · Pneumocystis versus invasive Aspergillus

Pneumocystis

Yeast-like fungus with cystic and trophic forms

Foamy alveolar exudate with septal reaction

Demonstration by targeted stains and PCR

Invasive Aspergillus

Filamentous septate hyphae with acute-angle branching

Marked tendency to vascular invasion

Can produce necrosis, hemorrhage and infarction

Slide 61 · Pneumocystis versus Cryptococcus

Pneumocystis

Typically a bilateral opportunistic pneumonia

Cyst profiles revealed by silver stain

No characteristic thick gelatinous capsule described

Cryptococcus

Encapsulated yeast

Mucicarmine and PAS can demonstrate capsule

Meningoencephalitis and characteristic CNS lesions are important

Slide 62 · HIV-related infiltrates are not always infectious

Pulmonary malignancy in the differential of HIV-related disease.

Kaposi sarcoma, non-Hodgkin lymphoma, and lung cancer are examples in the lung chapter.

A pulmonary opacity must not be attributed to Pneumocystis without adequate evaluation.

Infection

Drug-related pathology

Malignancy

Slide 63 · Case 1: Host risk and pulmonary pattern

A patient with advanced HIV infection develops a rapidly progressive bilateral pneumonia.

The CD4⁺ T-cell count is below the threshold highlighted.

A lower respiratory tract specimen is sent for organism-directed testing.

Which opportunistic fungus must be high on the initial differential?

Slide 64 · Case 1: Interpretation

P. Jirovecii is strongly suggested by the combination of advanced HIV and bilateral pneumonia.

That clinical pattern is not, by itself, species-level diagnostic proof.

Supportive specimen evidence may include characteristic staining, antibody-based tests or PCR.

Risk enrichment

Pulmonary phenotype

Detection

Slide 65 · Case 2: The limits of a wall stain

A lung sample contains honeycombed eosinophilic intra-alveolar material.

The pathologist selects a methenamine silver stain to look for Pneumocystis.

The question concerns which developmental forms the stain can display.

Why should the stain not be interpreted as a census of all Pneumocystis forms?

Slide 66 · Case 2: Interpretation

Methenamine silver stains wall-bearing cystic/ascus forms.

Trophic forms are not visualized by this wall-staining approach.

The stain’s biological target is narrower than the entire organism population.

Stained wall-bearing forms

Unstained trophic forms

Interpretation boundary

Slide 67 · Case 3: An elevated nonspecific marker

An immunocompromised patient has diffuse pulmonary abnormalities.

β-D-glucan is elevated during the diagnostic evaluation.

No organism-specific result has yet been provided.

Can β-D-glucan alone confirm Pneumocystis pneumonia?

Slide 68 · Case 3: Interpretation

No: β-D-glucan is not specific for Pneumocystis.

The result can contribute supporting information in the proper clinical setting.

Direct organism-directed or molecular assays remain important for attribution.

Supportive marker

Lack of species specificity

Targeted evidence

Slide 69 · Case 4: The differential remains open

An immunocompromised patient has a diffuse pulmonary infiltrate.

Pneumocystis is considered, but drug toxicity and CMV are also clinically plausible.

A preliminary morphologic assessment does not identify a causative organism.

Which principle prevents premature closure on a single etiology?

Slide 70 · Case 4: Interpretation

Diffuse pulmonary abnormalities have infectious and noninfectious causes.

Robbins also notes that two or more pathogens may be present in compromised patients.

Integrate distribution, microscopy, targeted assays, and the patient’s clinical course.

Multiple possible causes

Broader differential

Integrated evaluation

Slide 71 · Final synthesis: Three linked diagnostic levels

Host defense

Lung morphology

Agent detection

Host: Recognize the immunocompromised setting and relevant CD4⁺-related risk.

Lung: Recognize foamy intra-alveolar exudate plus interstitial reaction.

Agent: Use cell-wall stain, fluorescent antibody detection, or PCR; Treat β-D-glucan as nonspecific.

Slide 72 · Core distinctions to retain

Organism: Yeast-like fungus, historically misclassified as protozoal.

Disease: Opportunistic, predominantly pulmonary, potentially rapidly progressive.

Morphology: Honeycombed alveolar exudate, thickened septa, silver-positive cystic forms.

Diagnosis: Targeted detection with awareness of test-specific limitations.

Slide 73 · Reference framework and evidence boundaries

Primary: Robbins, Cotran & Kumar, Pathologic Basis of Disease, 11th ed. (2026), chapter 8, Pneumocystis Infections.

Context: Robbins chapters 6 (immune deficiency/HIV) and 15 (immunocompromised host pneumonia).

Textbook figure 8.45 informs the morphology; the copyrighted image has not been reproduced.

All constructed alveolar/organism drawings are original editable schematics, not clinical images.